"Honest to God, there are dozens of targets we could hit. We can afford to be generous and give a partner like Roche whatever they want," Arrakis CEO Michael Gilman said of the Roche collaboration, in which the privately held startup will help Roche develop drugs that target RNA, the element inside molecules that uses DNA instructions to create proteins. Roche will have exclusive rights to test and commercialize any drug candidates.

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), and Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), both leaders in the field of ribonucleic acid interference (RNAi) therapeutics, announced today the formation of a development and commercialization collaboration on investigational RNAi therapeutics for the treatment of alpha-1 antitrypsin (A1AT) deficiency-associated liver disease (alpha-1 liver disease). In addition, the companies have completed a cross-license of their respective intellectual property for Alnylam’s lumasiran and Dicerna’s nedosiran investigational programs for the treatment of primary hyperoxaluria (PH). These agreements will enhance and accelerate Alnylam’s and Dicerna’s ability to bring these orphan product candidates to market.

Dicerna provided an overview of its response to the COVID-19 pandemic and an update on business continuity and clinical development milestones.

It's been a good week for Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) shareholders, because the company has just...

Dicerna announced that Doug Fambrough, Ph.D., president and CEO, will present a corporate overview as part of the Jefferies Healthcare Conference.

DRNA earnings call for the period ending March 31, 2020.

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Investors in stocks with small market values know all too well that they usually underperform in down markets. The flip side is that small-cap stocks often lead the way when markets are headed higher again.Most small-cap investors can't wait for the market to turn. The S&P; 500 has lost 16% since it peaked on Feb. 19. As for the small-cap benchmark Russell 2000? It has tumbled more than 25%.This widespread pain among small caps might give investors pause about digging in. So we decided to suss out which stocks are holding up best, perhaps generating gains, and are set up for continued outperformance once businesses and markets get back to something resembling normal conditions.Sure enough, even today, there's no shortage of great ideas when it comes to small-cap stocks.To find the best candidates, we limited ourselves to companies with market capitalizations of between $1 billion and $2 billion. The stocks also had to outperform the S&P; 500 since the bear market kicked off almost three months ago.We further whittled the list down to stocks with an average broker recommendation of Buy or better. S&P; Capital IQ surveys analysts' stock ratings and scores them on a five-point scale, where 1.0 equals Strong Buy and 5.0 means Strong Sell. Any score of 2.0 or lower means that analysts, on average, rate the stock a Buy. The closer the score gets to 1.0, the stronger the Buy call. Lastly, we dug into research and analysts' estimates on the top-scoring names.From that pool, we landed on 11 of the best small-cap stocks that analysts love the most. Read on as we highlight each one. SEE ALSO: 50 Top Stock Picks That Billionaires Love

Dicerna Pharmaceuticals (DRNA) delivered earnings and revenue surprises of -210.71% and -42.92%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Dicerna announced that Douglas M. Fambrough, Ph.D., president and CEO, will present a corporate overview at two May investor conferences.

Dicerna announced that Douglas Pagán will become Dicerna’s CFO and a member of the Company’s executive leadership team, effective May 26, 2020.

Dicerna provided an overview of initial observations from the PHYOX™3 long-term, multidose trial evaluating nedosiran for PH1 types 1, 2 and 3.

By working together, the companies will create a unified front against two other rivals: Vertex Pharmaceuticals and Arrowhead Pharmaceuticals.

Dicerna today announced that the Company will release its first quarter 2020 financial results after market close on Thursday, May 7, 2020.

Companies in race to find treatment for genetic disease that can cause lung and liver disease Continue reading...

Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]

The analysts covering Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) delivered a dose of negativity to shareholders...

Dicerna today reported financial and operating results for the first quarter ended March 31, 2020.

Dicerna announced that the Company approved the grant of inducement stock options of common stock and restricted stock units among 13 employees.

Q1 2020 Dicerna Pharmaceuticals Inc Earnings Call